These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28089149)

  • 1. Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS.
    Farhan S; Clare RM; Jarai R; Giugliano RP; Lokhnygina Y; Harrington RA; Kristin Newby L; Huber K
    Int J Cardiol; 2017 Apr; 232():264-270. PubMed ID: 28089149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
    Wang TY; White JA; Tricoci P; Giugliano RP; Zeymer U; Harrington RA; Montalescot G; James SK; Van de Werf F; Armstrong PW; Braunwald E; Califf RM; Newby LK
    Circulation; 2011 Feb; 123(7):722-30. PubMed ID: 21300952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
    Bagai A; White JA; Lokhnygina Y; Giugliano RP; Van de Werf F; Montalescot G; Armstrong PW; Tricoci P; Gibson CM; Califf RM; Harrington RA; Newby LK
    Am Heart J; 2013 Sep; 166(3):466-73. PubMed ID: 24016495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
    Lopes RD; White JA; Tricoci P; White HD; Armstrong PW; Braunwald E; Giugliano RP; Harrington RA; Lewis BS; Brogan GX; Gibson CM; Califf RM; Newby LK
    Int J Cardiol; 2013 Sep; 167(6):2580-7. PubMed ID: 22795720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
    Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
    N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.
    Lindholm D; James SK; Bertilsson M; Becker RC; Cannon CP; Giannitsis E; Harrington RA; Himmelmann A; Kontny F; Siegbahn A; Steg PG; Storey RF; Velders MA; Weaver WD; Wallentin L;
    Clin Chem; 2017 Feb; 63(2):573-584. PubMed ID: 27932413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
    Pride YB; Mohanavelu S; Zorkun C; Kunadian V; Giugliano RP; Newby LK; Braunwald E; Califf RM; Harrington RA; Gibson CM;
    JACC Cardiovasc Interv; 2012 Sep; 5(9):927-35. PubMed ID: 22995880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).
    Kunadian V; Giugliano RP; Newby LK; Zorkun C; Guo J; Bagai A; Montalescot G; Braunwald E; Califf RM; Van de Werf F; Armstrong PW; Harrington R; Gibson CM
    Am J Cardiol; 2014 Apr; 113(8):1297-305. PubMed ID: 24607027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome.
    Eggers KM; Lagerqvist B; Venge P; Wallentin L; Lindahl B
    J Am Coll Cardiol; 2009 Jul; 54(4):357-64. PubMed ID: 19608034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study.
    He WF; Jiang L; Chen YY; Liu YH; Chen PY; Duan CY; Zeng LH; Fan HL; Wei XB; Guo W; Chen W; Li J; Li WS; Guo ZQ; Liu ZK; Tan N; Chen JY; He PC
    BMC Cardiovasc Disord; 2021 Apr; 21(1):202. PubMed ID: 33882836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.
    Buchner S; Debl K; Barlage S; Griese D; Fredersdorf S; Jeron A; Lubnow M; Müller T; Muders F; Holmer S; Riegger GA; Luchner A
    Clin Chem Lab Med; 2010 Jun; 48(6):875-81. PubMed ID: 20441480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of NT-proBNP for 30-day mortality in patients with non-ST-elevation acute coronary syndromes: a comparison with the GRACE and TIMI risk scores.
    Schellings DA; Adiyaman A; Dambrink JE; Gosselink AM; Kedhi E; Roolvink V; Ottervanger JP; Van't Hof AW
    Vasc Health Risk Manag; 2016; 12():471-476. PubMed ID: 27920547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
    Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
    Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial.
    Toleva O; Westerhout CM; Senaratne MP; Bode C; Lindroos M; Sulimov VA; Montalescot G; Newby LK; Giugliano RP; Van de Werf F; Armstrong PW
    Catheter Cardiovasc Interv; 2014 Nov; 84(6):934-42. PubMed ID: 24976083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
    Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
    Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NT-proBNP for prognostic and diagnostic evaluation in patients with acute coronary syndromes.
    Zdravkovic V; Mladenovic V; Colic M; Bankovic D; Lazic Z; Petrovic M; Simic I; Knezevic S; Pantovic S; Djukic A; Zdravkovic N
    Kardiol Pol; 2013; 71(5):472-9. PubMed ID: 23788087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial.
    Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD; Sabatine MS; Mehta SR; Steg PG
    Circ Cardiovasc Interv; 2018 Jun; 11(6):e006084. PubMed ID: 29895599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between plasma N-terminal pro-brain natriuretic peptide and GRACE risk stratification in non-ST-segment elevation acute coronary syndrome].
    Liu WX; Zhao H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 May; 40(5):373-7. PubMed ID: 22883085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes.
    Ndrepepa G; Braun S; Mehilli J; Niemöller K; Schömig A; Kastrati A
    Clin Res Cardiol; 2007 Jan; 96(1):30-7. PubMed ID: 17066344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score.
    Schellings DA; Adiyaman A; Giannitsis E; Hamm C; Suryapranata H; Ten Berg JM; Hoorntje JC; Van't Hof AW
    J Am Heart Assoc; 2014 Nov; 3(6):e001089. PubMed ID: 25389283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.